debt purchase agreement this debt purchase agreement ( the “ agreement ” ) made as of this _ 17th day of february, 2017 by and between lg capital funding, llc ( the “ seller ” ) and ghs investments, llc ( the “ buyer ” ). 1. purchase and sale of the convertible note upon the terms and conditions herein contained, at each closing as hereinafter defined, the seller hereby sells, assigns and transfers to the buyer and the buyer agrees to purchase from the seller the “ transferred rights ” of the seller and all rights thereto, free and clear of all liens, claims, pledges, mortgages, restrictions, obligations, security interests and encumbrances of any kind, nature and description. transferred rights shall mean all rights with respect to $ 563, 027. 81 in principal, accrued interest, and settlement premiums under those certain convertible promissory notes ( collectively, the " notes " ) issued to the seller by rich pharmaceuticals, inc. ( “ borrower ” or “ company ” ) in the principal face amounts as outlined in schedule 1 below. by its signatures hereto, the borrower accepts the assignment of the transferred rights to buyer and agrees that buyer may convert the transferred rights into shares of the company ’ s common stock. schedule 1 principal date of issuance present balance with interest, and settlement premiums $ 30, 000 " lg 1 " 5 / 26 / 16 8 % redeemable convertible note. $ 38, 106. 74 $ 19, 864. 73 " lg 2 " 6 / 8 / 16 - originally issued to typenex on 5 / 29 / 15 pursuant to a $ 362, 500 note and $ 19, 864. 73 assigned to lg on 6 / 6 / 2016. $ 26, 558. 87 $ 84, 250 " lg 3 " 6 / 10 / 16 - 8 % redeemable convertible note. $ 134, 213. 71 $ 29, 117. 91 " lg 4 " 6 / 23 / 16 - originally issued to auctus on 3 / 9 / 15 and assigned to lg 6 / 23 / 16. $ 44, 432. 65 $ 56, 000 " lg 5 " 6 / 24 / 16 8 % convertible redeemable note. $ 90, 075. 62 $ 58, 000 " lg 6 " 7 / 8 / 16 8 % convertible redeemable note